成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. PI3K/Akt/mTOR Apoptosis Autophagy Metabolic Enzyme/Protease
  3. PI3K Apoptosis Autophagy Endogenous Metabolite
  4. Myricetin

Myricetin  (Synonyms: 楊梅素; Cannabiscetin)

目錄號: HY-15097 純度: 98.42%
COA 產(chǎn)品使用指南 技術(shù)支持

Myricetin是常見的植物來源的類黃酮，具有廣泛的活性，包括強(qiáng)抗氧化，抗癌，抗糖尿病和抗炎活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Myricetin Chemical Structure

Myricetin Chemical Structure

CAS No. : 529-44-2

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥397
In-stock
25 mg ￥361
In-stock
50 mg ￥500
In-stock
100 mg ￥700
In-stock
200 mg ￥1000
In-stock
500 mg ￥1900
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Myricetin:

    Myricetin purchased from MCE. Usage Cited in: Int Immunopharmacol. 2019 Oct;75:105742.   [Abstract]

    Myricetin suppresses the generation of inflammatory mediators in IL-1β induced human chondrocytes. The protein expression of iNOS and COX-2 in chondrocytes is determined by western blots.

    • 生物活性

    • 實(shí)驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    14.8 mg/mL
    Compound: 23
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    		[PMID: 15568778]
    BV-2 IC50
    > 100 μM
    Compound: 2
    Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
    Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
    		[PMID: 27623545]
    CWR22R IC50
    13.1 μM
    Compound: 13
    Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
    Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
    		[PMID: 22789812]
    H9 EC50
    35 μM
    Compound: 16
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
    Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
    		[PMID: 8158164]
    H9 IC50
    69 μM
    Compound: 16
    Cytotoxicity against human H9 cells after 3 days
    Cytotoxicity against human H9 cells after 3 days
    		[PMID: 8158164]
    HCT-116 IC50
    > 20 μM
    Compound: Myricetin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32886510]
    HCT-116 IC50
    23 μM
    Compound: 3
    Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay
    Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay
    		[PMID: 22212721]
    HCT-116 IC50
    24 μM
    Compound: 3
    Growth inhibition of human HCT116 cells after 48 hrs by MTT assay
    Growth inhibition of human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22212721]
    HCT-116 IC50
    28.2 μM
    Compound: 206b
    Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay
    		[PMID: 30917303]
    HCT-116 IC50
    4.1 μM
    Compound: 3
    Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay
    Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay
    		[PMID: 22212721]
    HEK293 IC50
    > 10 μM
    Compound: 23
    Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
    Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
    		[PMID: 30943030]
    HepG2 IC50
    > 20 μM
    Compound: Myricetin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32886510]
    HK-2 IC50
    > 20 μM
    Compound: Myricetin
    Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32886510]
    HT-29 IC50
    > 20 μM
    Compound: Myricetin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32886510]
    HT-29 IC50
    2.12 μM
    Compound: Myricetin
    Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins
    Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins
    		[PMID: 24900447]
    HT-29 EC50
    3.02 μM
    Compound: Myricetin
    Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay
    Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay
    		[PMID: 24900447]
    Huh-7 CC50
    > 50 μM
    Compound: 28
    Cytotoxicity against human Huh7.5.1 cells by MTT assay
    Cytotoxicity against human Huh7.5.1 cells by MTT assay
    		[PMID: 22445328]
    Huh-7 EC50
    46.9 μM
    Compound: 28
    Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay
    Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay
    		[PMID: 22445328]
    Jurkat IC50
    10 μM
    Compound: Myricetin
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    		[PMID: 30776692]
    Jurkat IC50
    12 μM
    Compound: Myricetin
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    		[PMID: 30776692]
    L02 IC50
    > 20 μM
    Compound: Myricetin
    Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32886510]
    L929 EC50
    55 μM
    Compound: myricetin
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    		[PMID: 9287415]
    L929 EC50
    59 μM
    Compound: myricetin
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    		[PMID: 9287415]
    MCF7 IC50
    > 20 μM
    Compound: Myricetin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32886510]
    MCF7 IC50
    4.7 mg/mL
    Compound: 23
    Cytotoxicity against human MCF7 cells after 3 days by SRB assay
    Cytotoxicity against human MCF7 cells after 3 days by SRB assay
    		[PMID: 15568778]
    MV4-11 GI50
    > 50 μM
    Compound: 7
    Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    		[PMID: 23411073]
    Peritoneal macrophage IC50
    99 μM
    Compound: kp22
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    		[PMID: 27955927]
    RS4-11 GI50
    > 50 μM
    Compound: 7
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    		[PMID: 23411073]
    SK-BR-3 IC50
    > 100 μM
    Compound: 4
    Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis
    Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis
    		[PMID: 24548207]
    SK-BR-3 IC50
    > 100 μM
    Compound: 4
    Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis
    Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis
    		[PMID: 24548207]
    SK-BR-3 IC50
    > 100 μM
    Compound: 4
    Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis
    Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis
    		[PMID: 24548207]
    SK-BR-3 IC50
    13.5 μM
    Compound: 4
    Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay
    Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay
    		[PMID: 24548207]
    U2OS EC50
    14.7 μM
    Compound: Myricetin
    Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay
    Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay
    		[PMID: 24900447]
    體外研究
    (In Vitro)

    Myricetin 對多種自由基和離子具有清除活性。它在超氧化物歧化酶 (SOD) 樣活性測定[1]中表現(xiàn)出較差的活性 (IC50 值=1.4 mg/mL)。它通過調(diào)節(jié) PI3K/Akt 和 MAPK 信號通路防止癌細(xì)胞因細(xì)胞凋亡而死亡[2]。
    Myricetin 通過消除皮膚中的致病自由基而表現(xiàn)出抗光老化作用。Myricetin 能夠抑制小鼠皮膚表皮 JB6 P+ 細(xì)胞中 UVB 誘導(dǎo)的 COX-2 表達(dá)。它抑制 UVB 誘導(dǎo)的激活蛋白 1 和 NF-κβ 的啟動，以及 Fyn 激酶活性[1]。
    Myricetin 以劑量依賴性方式抑制 SKOV3 卵巢癌細(xì)胞的活力。它誘導(dǎo) DNA DSBs 和 ER 應(yīng)激，從而導(dǎo)致 SKOV3 細(xì)胞凋亡[3]。
    Myricetin 抑制人 Hsp70 超過 80%，IC50 值分別為 83、11 和 12 μM[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    用 Myricetin 處理原位胰腺腫瘤可使腫瘤消退并減少轉(zhuǎn)移擴(kuò)散[2]。暴露于 150 μM Myricetin 可分別抑制由 ADP、花生四烯酸、膠原蛋白和 PAF 誘導(dǎo)的兔血小板聚集 14%、26%、5% 和 49%[5]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    318.24

    Formula

    C15H10O8
    CAS 號
    性狀

    固體

    顏色

    Light yellow to yellow

    中文名稱

    楊梅素；楊梅酮
    結(jié)構(gòu)分類
    初始來源
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗： 

    DMSO 中的溶解度 : ≥ 31 mg/mL (97.41 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    Ethanol 中的溶解度 : 28.57 mg/mL (89.78 mM; 超聲助溶)

    * "≥" means soluble, but saturation unknown.

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.1423 mL 15.7114 mL 31.4228 mL
    5 mM 0.6285 mL 3.1423 mL 6.2846 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實(shí)驗：

    請根據(jù)您的 實(shí)驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實(shí)驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.54 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (6.54 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動物溶解方案計算器
    請輸入動物實(shí)驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實(shí)驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實(shí)驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料
    參考文獻(xiàn)
    Cell Assay
    [2]

    Pancreatic cancer cells (MIA PaCa-2, Panc-1 or S2-013) or normal pancreatic ductal cells (PDCs) are treated with myricetin (12.5–200 μM). Cell viability is determined using the Dojindo Cell Counting Kit-8. Cells are seeded onto a 96-well plate at 1×104 cells per well and allowed to adhere overnight. After treatment with myricetin at various concentrations for 24 hours, 10 μL of the tetrazolium substrate is added to each well of the plate. Plates are incubated at 37°C for 1 hour, after which the absorbance at 450 nm is measured[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice: Mice are given daily intraperitoneal injections of myricetin (30mg/kg in the MIA PaCa-2 model and 50mg/kg in the S2-013 model) or vehicle (DMSO) for 35 days (MIA PaCa-2 model) or 18 days (S2-013 model). Ultrasound measurements are performed at regular intervals to monitor tumor growth. At the end of the in vivo experiment, tumor size is measured using calipers and tumor volume is calculated[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 3.1423 mL 15.7114 mL 31.4228 mL 78.5571 mL
    5 mM 0.6285 mL 3.1423 mL 6.2846 mL 15.7114 mL
    10 mM 0.3142 mL 1.5711 mL 3.1423 mL 7.8557 mL
    15 mM 0.2095 mL 1.0474 mL 2.0949 mL 5.2371 mL
    20 mM 0.1571 mL 0.7856 mL 1.5711 mL 3.9279 mL
    25 mM 0.1257 mL 0.6285 mL 1.2569 mL 3.1423 mL
    30 mM 0.1047 mL 0.5237 mL 1.0474 mL 2.6186 mL
    40 mM 0.0786 mL 0.3928 mL 0.7856 mL 1.9639 mL
    50 mM 0.0628 mL 0.3142 mL 0.6285 mL 1.5711 mL
    60 mM 0.0524 mL 0.2619 mL 0.5237 mL 1.3093 mL
    80 mM 0.0393 mL 0.1964 mL 0.3928 mL 0.9820 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Myricetin
    目錄號：
    HY-15097
    需求量：